GoodRx Holdings (GDRX) Cash from Operations (2019 - 2026)

GoodRx Holdings has disclosed Cash from Operations across 8 years of filings, most recently posting $80.8 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 63.03% year-over-year to $80.8 million; the TTM figure through Jun 2026 stood at $201.6 million (up 5.76% YoY), while the FY2025 annual figure was $167.9 million, down 8.69% from the prior year.
• Cash from Operations came in at $80.8 million for Q2 2026 at GoodRx Holdings, up from $11.8 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $86.9 million in Q3 2024 to a low of $9.4 million in Q1 2025.
• Average Cash from Operations over 5 years is $40.5 million, with a median of $33.3 million recorded in 2022.
• The largest YoY upside for Cash from Operations was 411.08% in 2025 against a maximum downside of 77.9% in 2025.
• Over 5 years, Cash from Operations stood at $31.9 million in 2022, then plunged by 50.22% to $15.9 million in 2023, then jumped by 181.97% to $44.7 million in 2024, then fell by 26.5% to $32.9 million in 2025, then soared by 145.78% to $80.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $80.8 million in Q2 2026, $11.8 million in Q1 2026, and $32.9 million in Q4 2025.